Fuse Science Announces the Launch of its Analgesic and Diabetic Oral Fuse Delivery (OFD) Research Project Platforms
AVENTURA, Fla., Dec. 20, 2011 /PRNewswire/ -- Double Eagle Holdings, Ltd. (OTCQB: DROP), the parent company of Fuse Science, Inc. ( www.fusescience.com), announced today the formal launch of its Hypoglycemic, Hyperglycemic, and Analgesic project platforms for the advancement of its OTC and pharmaceutical licensing efforts.
Some of the proprietary science platforms that Fuse Science deals with are oral fuse delivery technologies (OFD's). These OFD's are placed under the tongue or in the inner cheek of the patient where they are absorbed and release the applicable active or nutrient into the blood stream. OFD's do not require water and may be more convenient to take than liquids or injections. OFD's are especially designed to be very useful with pediatric and geriatric patients or anyone in need of faster absorption of a given active into the blood stream that bypasses the GI track, providing an alternative to the more traditional invasive drug delivery systems.
"Today we announce the further advancement of the true core of our Powered by Fuse™ technology," said Brian Tuffin, Fuse Science Chief Executive Officer. "It is with high confidence that we advance our OFD Analgesic, Hypoglycemic and Hyperglycemic project platforms with the objective of completing our pediatric and adult formulations to provide an effective sublingual and/or Buccal delivery alternative for the respective drugs."
The business opportunities from these project platforms are as follows:
- The side effects of aspirin on the stomach include bleeding of the abdomen and deterioration of the stomach lining. By bypassing the GI track with our drop technology we intend to improve performance and usage in the $2.5 billion adult analgesic category.
- The largest disease state globally is diabetes with an